International Stem Cell Corp. (OTCQB:ISCO) Proprietary Stem Cell Technology Creates Unique Business Portfolio
International Stem Cell is a 12-year old biotech company headquartered in Carlsbad, Calif., focused on the development of therapeutic, biomedical and cosmeutical products for both domestic and international commercialization.
The company's operations branch into two channels. The first is developing products based on human parthenogenetic stem cells which the company develops into other cell types such as liver cells for the treatment of congential and acquired liver diseases; islet cells for the treatment of diabetes; neuronal cells for the treatment of Parkinson's disease and other central nervous system disorders; and 3 dimensional eye structures to treat degenerative retinal diseases, corneal blindness, and to speed corneal healing.
ISCO also funnels its stem cell technology to develop, manufacture, and market cosmetic skin care products for use in pharmaceutical, academic, and government research organizations. The company executes the operation of this initiative through its subsidiary, Lifeline Skin Care. The brand in June signed distribution agreements to sell its products in Thailand and Viet Nam where stem cells are considered the most important medical technology of the 21st Century.
While ISCO's two units significantly differ, both are based on the company's proprietary class of stem cells, human parthenogenetic stem cells (hpSCs), which are created from unfertilized human oocytes (eggs). Because the oocytes are not fertilized, no viable human embryo is created or destroyed. These hpSCs can be immune-matched to millions of people, making them applicable to a large demographic and for treatment of a wide range of indications, as ISCO is working to demonstrate.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net